Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.8 AUD | -1.16% | -2.64% | -24.59% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.59% | 1.64B | |
+48.53% | 779B | |
+40.67% | 631B | |
-6.37% | 354B | |
+20.93% | 333B | |
+8.21% | 301B | |
+16.75% | 249B | |
-1.19% | 216B | |
+10.85% | 214B | |
+4.40% | 163B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Appoints Lauren Frazer as Chief Financial Officer, Effective August 1, 2020